CDC Advisers Back RSV Vaccines in Older Adults

Published on June 21, 2023

A team of experts from the CDC has given their stamp of approval for the use of Pfizer and GSK vaccines to protect adults aged 60 and above from severe respiratory syncytial virus (RSV) infections. Just like how a superhero squad teams up to defeat villains, these vaccines come together to combat RSV and keep our beloved senior citizens healthy. RSV is like a sneaky villain that targets the respiratory system, causing coughing, wheezing, and difficulty breathing. The CDC advisers recognize the importance of protecting older adults from this potentially dangerous virus, especially when their immune systems may be more vulnerable. But here’s the exciting part: by vaccinating older adults, we also indirectly shield younger individuals who have contact with them, like grandparents spending quality time with their grandchildren! This creates a stronger defense against RSV transmission in the community. To learn more about the benefits and effectiveness of these RSV vaccines, don your scientist cape and dig into the underlying research!

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Wednesday recommended that adults aged 60 and above may receive the recently approved vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infections….

Read Full Article (External Site)

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>